Findings from a recent study suggest a possible association between vitamin D and disease severity among patients with psoriasis. For details from the study, including whether vitamin D supplementation is beneficial, read more.

News

News
Friday, October 20, 2017
Patients with psoriatic arthritis, rheumatoid arthritis, or ankylosing spondylitis who switched from an originator treatment to a biosimilar stopped taking the biosimilar medication within 6 months.
News
Wednesday, October 18, 2017
Researchers recently examined disease activity in patients treated for psoriatic arthritis.
News
Monday, October 2, 2017
Researchers have recently examined the risk of heart attack and stroke in patients with psoriasis.
News
Wednesday, September 27, 2017
Two recent phase 3 trials examined the safety and efficacy of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis.

NPF Endorsed Articles

NPF Endorsed Articles
Friday, September 19, 2014
This article, based on a presentation that was given at the Interdisciplinary Autoimmune Summit held in June 2014 in Las Vegas, describes how to select the right biologic for a patient who has not previously received biologic therapy.   
NPF Endorsed Articles
Thursday, August 21, 2014
The interleukin-17A inhibitor secukinumab was effective in the treatment of psoriasis, according to 2 large studies. 
NPF Endorsed Articles
Tuesday, July 22, 2014
The link between psoriasis and other medical conditions such as psoriatic arthritis (PsA), cardiovascular disease, metabolic disorder, inflammatory bowel disease, psychiatric disorders, lymphoma and ocular disease is being recognized by a growing body of peer review literature. 

Research in Review

Research in Review
Wednesday, May 11, 2016
Make sure you do not mistake signs of psoriasis in patients of color.
Research in Review
Tuesday, April 19, 2016
Posters presented at The Winter Clinical Dermatology Conference-Hawaii look at treatment options for psoriasis.
Research in Review
Monday, March 28, 2016
Gary Goldenberg, MD, discusses the latest oral agents for individuals living with psoriasis.
Research in Review
Thursday, February 11, 2016
In this excerpt from the recently published book, Practical Psoriasis Management, the authors discuss the use of secukinumab for moderate-to-severe psoriasis.